Return to study ST001236 main page
MB Sample ID: SA088656
Local Sample ID: | CA209009-9-97_week 9 |
Subject ID: | SU001304 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU001304 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Factors:
Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
---|---|---|---|---|
CA209009-9-97_week 9 | SA088656 | FL012997 | week 9 | Time point |
CA209009-9-97_week 9 | SA088656 | FL012997 | 1 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS) |
CA209009-9-97_week 9 | SA088656 | FL012997 | 2 | Nivolumab Dose (mg/kg) |
Collection:
Collection ID: | CO001298 |
Collection Summary: | Serum was collected at the specified time-points by centrifugation at 4000g for 4 minutes at 25°C within 2 hours of collection. Samples were frozen immediately and stored at or below -20°C for up to two months followed by storage at -80°C. |
Sample Type: | Blood (serum) |
Storage Conditions: | Described in summary |
Treatment:
Treatment ID: | TR001319 |
Treatment Summary: | In CA209-009, NCT01358721, Nivolumab was administered intravenously every 3 weeks at 0.3, 2, or 10 mg/kg to previously treated patients and 10 mg/kg to treatment-naïve patients with metastatic renal cell carcinoma (mRCC). |
Treatment Protocol ID: | NCT01358721 |
Sample Preparation:
Sampleprep ID: | SP001312 |
Sampleprep Summary: | Serum samples (10 µL) were extracted using 90 µL of 74.9:24.9:0.2 (v/v/v) acetonitrile/methanol/formic acid containing stable isotope-labeled internal standards (0.2 ng/µL valine-d8, Isotec; 0.2 ng/µL phenylalanine-d8, Cambridge Isotope Laboratories). The samples were centrifuged (10 min, 9000g, 4ºC) and the supernatants were transferred to autosampler vials with de-activated inserts (Waters). |
Combined analysis:
Analysis ID | AN002054 |
---|---|
Analysis type | MS |
Chromatography type | HILIC |
Chromatography system | Shimadzu Nexera X2 |
Column | Waters Atlantis HILIC (150 x 2.1mm) |
MS Type | ESI |
MS instrument type | Orbitrap |
MS instrument name | Thermo Q Exactive Orbitrap |
Ion Mode | POSITIVE |
Units | Log10(Peak Area) |
Chromatography:
Chromatography ID: | CH001493 |
Chromatography Summary: | Extracts (10 µL) were injected onto a 150 x 2.1 mm Atlantis HILIC column (Waters). The column was eluted isocratically at a flow rate of 250 µL/min with 5% mobile phase A (10 mM ammonium formate and 0.1% formic acid in water) for 1 minute followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 minutes |
Instrument Name: | Shimadzu Nexera X2 |
Column Name: | Waters Atlantis HILIC (150 x 2.1mm) |
Column Temperature: | 30 |
Flow Rate: | 250 µL/min |
Solvent A: | 100% water; 0.1% formic acid; 10 mM ammonium formate |
Solvent B: | 100% acetonitrile; 0.1% formic acid |
Chromatography Type: | HILIC |
MS:
MS ID: | MS001906 |
Analysis ID: | AN002054 |
Instrument Name: | Thermo Q Exactive Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | High resolution, accurate mass data were acquired using a system comprised of a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp.; Marlborough, MA) coupled to a Q Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Fisher Scientific; Waltham, MA). MS analyses were carried out using electrospray ionization in the positive ion mode using full scan analysis over 70-800 m/z at 70,000 resolution and 3 Hz data acquisition rate. Other MS settings were: sheath gas 40, sweep gas 2, spray voltage 3.5 kV, capillary temperature 350°C, S-lens RF 40, heater temperature 300°C, microscans 1, automatic gain control target 1e6, and maximum ion time 250 ms. Raw data were processed using TraceFinder software (Thermo Fisher Scientific; Waltham, MA) and Progenesis QI (Nonlinear Dynamics; Newcastle upon Tyne, UK). The identities of 202 profiled metabolites were confirmed using reference standards. |
Ion Mode: | POSITIVE |